Dendrimer-based compositions and methods are provided, that are useful for administering pharmaceutical compositions to target cells and tissues for treatment of ocular diseases including macular degeneration, diabetic retinopathy, and retinitis pigmentosa.

The present invention relates to nanoparticles comprising nucleic acids coated with a (biodegradable) polymer for reversible immobilization and/or controlled release of the nucleic acid comprising nanoparticles. Furthermore, the present invention is directed to medical or diagnostic devices, particularly stents and implants coated by a (biodegradable) polymer with the nucleic acid comprising nanoparticles for reversible immobilization and/or controlled release. Furthermore, the present invention is directed to the use of these nanoparticles coated with a (biodegradable) polymer and to the use of medical devices and implants coated by the (biodegradable) polymer with these nucleic acid comprising nanoparticles in the prophylactic or therapeutic treatment of diseases, particularly in the prevention or treatment of restenosis, calicification, foreign body reaction, or inflammation. Additionally, the present invention is directed to a method of preparing these nucleic acid comprising nanoparticles coated with a (biodegradable) polymer and to a method for coating nucleic acid comprising nanoparticles by a (biodegradable) polymer on medical or diagnostic devices.

This application provides a high throughput method of making nanoparticles that utilizes plates comprising wells (e.g., 96-well plates).

Provided herein are compositions that comprise negatively charged particles and methods of making and using the same. Also provided are methods of reducing or treating Cytokine Storm Syndrome (CSS) or Acute Rcspiratoiy Distress Syndrome (ARDS).

The present invention relates to an oil-in-water nanoemulsion comprising an oil phase comprising at least one essential oil or water-immiscible phase comprising a hydrophobic polymer and/or a hydrophobic active dispersed in an aqueous phase, said nanoemulsion comprising nanometric droplets of said essential oil or said active with an interface consisting of amphiphilic derivatives of chitosan and at least one fatty acid, obtained by ionic interaction between the deacetylated amino groups of said chitosan and the carboxylic groups of said fatty acid.

Described herein are methods and systems for the preparation of a brain targeted cerium oxide nanop article (CeNP) and its application in treating central neuronal system diseases. The brain targeted CeNP (T-CeNP) can effectively pass the blood brain barrier and specifically target brain tissue and exhibit anti-inflammatory and anti-oxidant effects.

Carvedilol parenteral sustained release systems by IV infusion, injection, or subcutaneous routes are disclosed. Preparation of carvedilol disperse systems such as liposomes, biodegradable microparticles or nanparticles, and polymeric microparticles or nanparticles have been presented in the present invention. Compositions containing carvedilol encapsulated in liposomes showed higher bioavailability and lower clearance rate than that of the free solution after intravenous administration. In vitro release of those liposomes in buffer solutions shows drug extended release over 48 hours, and correspondingly the in vivo animal data shows that parenteral administration of carvedilol encapsulated in liposomal materials has sustained release PK profile.

Provided is a nanoparticle including a water-soluble protein, a glucan and a hydrophilic active agent, the glucan being at least partially cross-linked by a metaphosphate.

The present disclosure relates to compositions and methods for the regeneration and/or restoration of hair cells utilizing a composition or an agent that decreases expression of a gene in a tissue of the inner ear and a second agent.

The invention provides compositions comprising microparticles wherein the microparticles comprise at least one adenosine 2a receptor antagonist (A2ARA), at least one pharmaceutically acceptable polymer and at least one pharmaceutically acceptable negatively charged agent wherein the microparticles optionally have a highly negative zeta potential of less than about −40 mV. The invention also provides pharmaceutical compositions of the microparticles of the invention and methods of using the compositions of the invention to enhance an immune response in a patient in need thereof and as anti-cancer immunotherapy.